Copertina

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	David W. Dodick, Stewart J. Tepper, Jessica Ailani, Ani C. Khodavirdi, Nico Pannacciulli, Alan Fu, Shia T. Kent, Karminder Gill, Robert Urman, Sam S. Oh
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
di: Gabriel Paiva da Silva Lima, et al.
Pubblicazione: (2025)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
di: Lawrence C. Newman, et al.
Pubblicazione: (2025)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
di: Jessica Ailani, et al.
Pubblicazione: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
di: Shuu‐Jiun Wang, et al.
Pubblicazione: (2024)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
di: Samantha C. Shao, et al.
Pubblicazione: (2024)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
di: Jessica Ailani, et al.
Pubblicazione: (2024)

Assessing blood pressure changes and hypertension‐related outcomes in patients with migraine treated with erenumab: A systematic review and meta‐analysis
di: Luana Miyahira Makita, et al.
Pubblicazione: (2025)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
di: Jessica Ailani, et al.
Pubblicazione: (2025)

A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States
di: Shivang Joshi, et al.
Pubblicazione: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
di: Dawn C. Buse, et al.
Pubblicazione: (2026)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
di: Stephen D. Silberstein, et al.
Pubblicazione: (2024)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

A retrospective analysis of the use of candesartan for migraine prevention in adolescents
di: Irene Patniyot, et al.
Pubblicazione: (2024)

Effectiveness and acceptability of oral migraine preventives: A prospective, observational study
di: Hedda S. Riise, et al.
Pubblicazione: (2026)

Behavioral interventions for migraine prevention: A systematic review and meta‐analysis
di: Jonathan R. Treadwell, et al.
Pubblicazione: (2025)

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
di: Todd J. Schwedt, et al.
Pubblicazione: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
di: Inga Zalia Tummoszeit, et al.
Pubblicazione: (2024)

Substance use in a Dutch migraine cohort compared with the general population
di: Thomas C. van den Hoek, et al.
Pubblicazione: (2024)

Do antithrombotic drugs have a role in migraine prevention? A systematic review
di: Federico De Santis, et al.
Pubblicazione: (2025)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
di: Andrew Blumenfeld, et al.
Pubblicazione: (2024)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
di: Joanna K. Bougie, et al.
Pubblicazione: (2024)

Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study
di: Seonyoung Kang, et al.
Pubblicazione: (2024)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
di: Samuel K. Peasah, et al.
Pubblicazione: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
di: Julia Peris‐Subiza, et al.
Pubblicazione: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
di: Geneviève Tourigny‐Ruel, et al.
Pubblicazione: (2026)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
di: Alex Jaimes, et al.
Pubblicazione: (2024)

Exploring the relationship between pain catastrophizing and migraine in youth: A longitudinal clinical cohort study
di: Alexis Espanioli, et al.
Pubblicazione: (2025)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
di: Emmanuelle A. D. Schindler, et al.
Pubblicazione: (2025)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
di: Dawn C. Buse, et al.
Pubblicazione: (2024)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
di: Muneto Tatsumoto, et al.
Pubblicazione: (2024)

Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study
di: Maggie R. Mittleman, et al.
Pubblicazione: (2024)

Maternal and child mental health and incident migraine in adolescence: An “All Our Families” prospective cohort study
di: Kirsten Sjonnesen, et al.
Pubblicazione: (2026)

Association between obstructive sleep apnea and migraine: A United States population‐based cohort study
di: Thomas Yen‐Ting Chen, et al.
Pubblicazione: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)